Patents by Inventor Jutta Deckert

Jutta Deckert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11104740
    Abstract: The invention generally relates to antibodies that bind to human CD37 and diagnostic assays for CD37-based therapies.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: August 31, 2021
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Jutta Deckert, Daniel Tavares, Lingyun Rui, Sven Loebrich, Meghan Puopolo
  • Publication number: 20200408765
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Publication number: 20200270361
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 27, 2020
    Inventors: Jutta DECKERT, Julianto SETIADY, Peter U. PARK
  • Patent number: 10556958
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 11, 2020
    Assignee: Debiopharm International, S.A.
    Inventors: Jutta Deckert, Julianto Setiady, Peter U. Park
  • Publication number: 20190218303
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: December 17, 2018
    Publication date: July 18, 2019
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Publication number: 20190183788
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 20, 2019
    Inventors: Angela Romanelli, Rodrigo R. Ruiz-Soto, Jose Ponte, Jutta Deckert, Jan Pinkas
  • Patent number: 10202460
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 12, 2019
    Assignee: Debiopharm International, S.A.
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Publication number: 20180244795
    Abstract: The invention generally relates to antibodies that bind to human CD37 and diagnostic assays for CD37-based therapies.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 30, 2018
    Applicant: DEBIOPHARM INTERNATIONAL,S.A.
    Inventors: Jutta DECKERT, Daniel TAVARES, LingYun RUI, Sven LOEBRICH, Megan KELLY
  • Publication number: 20180230218
    Abstract: MET is a receptor tyrosine kinase found on the surface of tumor cells. The present invention includes anti-MET antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
    Type: Application
    Filed: January 3, 2018
    Publication date: August 16, 2018
    Inventors: Thomas Chittenden, Jutta Deckert, Stuart William Hicks, Katharine C. Lai, Peter U. Park, Lingyun Rui, Daniel J. Tavares, Neeraj Kohli
  • Publication number: 20170343550
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic rnyelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma.
    Type: Application
    Filed: January 9, 2017
    Publication date: November 30, 2017
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Publication number: 20170000900
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Application
    Filed: June 2, 2016
    Publication date: January 5, 2017
    Inventors: Angela ROMANELLI, Rodrigo R. RUIZ-SOTO, Jose PONTE, Jutta DECKERT, Jan PINKAS
  • Publication number: 20160340438
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 24, 2016
    Inventors: Jutta DECKERT, Julianto SETIADY, Peter U. PARK
  • Publication number: 20160326258
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: April 15, 2016
    Publication date: November 10, 2016
    Inventors: Jutta DECKERT, Peter PARK, Daniel TAVARES, Lingyun RUI
  • Patent number: 9447189
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 20, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Julianto Setiady, Peter U. Park
  • Patent number: 9346887
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 24, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • Publication number: 20160115238
    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 23-25, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 26-28, respectively.
    Type: Application
    Filed: September 16, 2015
    Publication date: April 28, 2016
    Inventors: Jutta DECKERT, Daniel J. Tavares, Peter U. Park
  • Publication number: 20160108126
    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively.
    Type: Application
    Filed: September 16, 2015
    Publication date: April 21, 2016
    Inventors: Jutta DECKERT, Lingyun Rui, Peter U. Park
  • Patent number: 9314522
    Abstract: Pharmaceutical composition comprising an antibody specifically recognizing CD38 and bortezomib.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: April 19, 2016
    Assignee: Sanofi
    Inventors: Jutta Deckert, Pascale Lejeune, Michele Mayo, Peter U. Park
  • Publication number: 20150343077
    Abstract: Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: May 12, 2015
    Publication date: December 3, 2015
    Inventors: Jutta DECKERT, Robert J. LUTZ, Joanne Elizabeth Sarah SCHINDLER, Rodrigo Ricardo RUIZ SOTO
  • Patent number: 9173961
    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 3, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Lingyun Rui, Peter U. Park